AZNStockAstrazeneca plc - ADR
Verdicts genuinely change. Free email alert the moment AZN's does — no target price to set, unlike a price alert.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Methodology breakdown computing — it will appear here on its own.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Astrazeneca plc - ADR (AZN) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-31). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 433 compliant Healthcare stocks we track. See compliant Healthcare stocks →
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for AZN — this runs off the critical path so the page paints first. It will appear here on its own.
Shariah-compliant alternatives
Compliant companies in Drug Manufacturers - General listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| LLYLilly(Eli) & Co | $1.2T | — |
| JNJJohnson & Johnson | $658.0B | — |
| ABBVAbbvie Inc | $467.4B | — |
| MRKMerck & Co Inc | $371.7B | $132.80-3.61% |
| NVSNovartis AG - ADR | $306.5B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold AZN
10 of the 208 funds whose filed holdings we currently hold own AZN shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns AZN.
Shariah funds| Fund | AZN in fund | Fund compliant by weight |
|---|---|---|
| UMMA Wahed Dow Jones Islamic World ETF | 2.50% | 89% |
| SPWO SP Funds S&P World (ex-US) ETF | 1.33% | 87% |
| Fund | AZN in fund | Fund compliant by weight |
|---|---|---|
| LBRIX ClearBridge Dividend Strategy Fund | 1.32% | 46% |
| LAFGX Lord Abbett International Growth Fund Also LASGX | 1.23% | 75% |
| TGLB T. Rowe Price Global Equity ETF | 0.94% | 50% |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.88% | 41% |
| MIINX BNY Mellon International Fund | 0.85% | 34% |
| TVAL T. Rowe Price Value ETF | 0.63% | 42% |
| LBSAX Columbia Dividend Income Fund | 0.52% | 52% |
| FIDI Fidelity International High Dividend ETF | 0.38% | 22% |
Sorted by AZN’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names AZN once, so a bond is not counted as the shares; 1 more fund name AZN in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Israel Englander | Millennium Management | $1,913M | 0.6% | 2026-09-30 |
| Ken Fisher | Fisher Asset Management | $1,857M | 0.5% | 2026-09-30 |
| Sarah Ketterer | Causeway Capital Management | $1,798M | 20.2% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $771M | 0.4% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $410M | 0.0% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $280M | 0.3% | 2026-09-30 |
| Jefferies | Jefferies Financial Group | $66M | 0.5% | 2026-09-30 |
| Hotchkis & Wiley | Hotchkis & Wiley Capital Management | $27M | 0.1% | 2026-09-30 |
| Larry Robbins | Glenview Capital Management | $20M | 0.3% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $16M | 0.0% | 2026-09-30 |
| Dodge & Cox | Dodge & Cox | $9M | 0.0% | 2026-09-30 |
| Azzad Asset Management | Azzad Asset Management | $7M | 0.7% | 2026-09-30 |
| Saturna Capital | Amana Mutual Funds Trust | $6M | 0.1% | 2026-09-30 |
| Ron Baron | Baron Capital (BAMCO) | $5M | 0.0% | 2026-09-30 |
| Paul Tudor Jones | Tudor Investment Corp | $3M | 0.0% | 2026-09-30 |
| Polen Capital | Polen Capital Management | $2M | 0.0% | 2026-09-30 |
| Ray Dalio | Bridgewater Associates | $1M | 0.0% | 2026-09-30 |
| Sallie Krawcheck | Ellevest | $1M | 0.1% | 2026-09-30 |
| Joel Greenblatt | Gotham Asset Management | $1M | 0.0% | 2026-09-30 |
| Lee Ainslie | Maverick Capital | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 45.20 | NEUTRAL |
| Stochastic %K (14) | 5.10 | BUY |
| CCI (20) | -65.56 | NEUTRAL |
| Williams %R (14) | -94.90 | BUY |
| MACD (12,26,9) | -1.56 | SELL |
| ROC (10) | -6.35 | SELL |
| Momentum (10) | -11.87 | SELL |
| EMA (10) | 181.42 | SELL |
| SMA (10) | 183.69 | SELL |
| EMA (20) | 179.73 | SELL |
| SMA (20) | 181.37 | SELL |
| EMA (30) | 177.23 | BUY |
| SMA (30) | 175.62 | BUY |
| EMA (50) | 174.06 | BUY |
| SMA (50) | 170.42 | BUY |
| EMA (100) | 172.95 | BUY |
| SMA (100) | 168.84 | BUY |
| EMA (200) | 178.35 | BUY |
| SMA (200) | 179.96 | SELL |
About Astrazeneca plc - ADR
Healthcare · Drug Manufacturers - General
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
Background via Yahoo Finance — informational, not part of the verdict.
🟢 STRONG BUY SETUP
Strong confluence across multiple layers — outperforming the market by 12.3%, RSI in healthy zone, Wall Street broadly bullish. High conviction entry. Use `!plan AZN [entry] [stop] [target]` to size the position properly.
Scores: 4 bullish / 0 bearish
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 64 |
| ⏰ 4H | BEARISH | 56 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NEUTRAL 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.